We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
New recommendations based on extensive public engagement set out how the NHS could give patients faster access to AI advances with proportionate safeguards to protect patient safety and maintain high levels of trust.
New partnership to create health innovation sandbox that will test promising new technologies and build evidence to accelerate the safe adoption of technologies, including AI, in the NHS.
Proposed amendments to support information sharing, regulatory reform and the future development of a medical device licensing regime.
Avacopan Vifor is used in the treatment of some rare autoimmune diseases affecting small blood vessels.
Wales’ connected health and life sciences ecosystem creates opportunities to support innovation from development through to adoption, helping new products reach patients while supporting investment and growth.
While most patients implanted with these hip replacements have well-functioning hips and are unlikely to develop serious problems, a small number may develop issues.
MHRA advises parents and carers against using rectal catheters sold for personal use (known as gas and colic relievers) in babies.
MHRA publishes position paper clarifying the UK licencing route for microbiome-based medicines, supporting developers to bring these innovative therapies to patients.
As with any medicine, the MHRA will keep the safety and effectiveness of vimseltinib (romvizma) under close review.
Medicines and medical devices regulator issues health advice for teens off to university.
Vaccination is one of the most effective and safest ways to protect against many serious infectious diseases
The MHRA has become aware of a number of medical devices being supplied on the UK market that do not comply with the requirements of the UK Medical Device Regulations or with the EU Medical Devices Regulation.
As with all GLP-1 receptor agonists, the MHRA will keep the safety and effectiveness of orforglipron under close review.
Some medicines can make you more sensitive to the sun or increase the risk of dehydration without you realising it. The MHRA is encouraging people to know the risks and stay protected this summer.
As with any medicinal product, the MHRA will keep the safety and effectiveness of remibrutinib under close review.
Innovative investigational products for liver cancer and dementia recognised through the Innovative Licensing and Access Pathway ahead of next application round opening.
Aficamten is recommended by NICE at the same time it was approved by the MHRA, thanks to improvements driven by closer working between the two organisations.
The London sandbox is a secure environment designed to safely test AI-enabled devices in a real-world environment so patients can benefit more quickly.
The Medicines and Healthcare products Regulatory Agency has published guidance, developed in close partnership with NHS England, clarifying how existing medical device law applies to ambient voice technology (AVT) products used in health and care settings in Great Britain.
Simple steps to help keep your essential medical equipment working safely when temperatures rise.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).